Furthermore, there doesnt appear to be an issue with the overdiagnosis of hyperthyroidism as there is with hypothyroid disorders
[DOI] [PubMed] [Google Scholar] 162.Zhao Y, Zhang X, Wang Y, et al
A qualified healthcare provider should evaluate whether GLP-1 treatment is appropriate for any individual under 30 years old, weighing comorbidities, weight loss goals, diabetes status, and long-term safety data gaps
This drug may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate)
Thus, based on the market analysis, the rise in the stringent regulatory standards hinders the L-carnitine market demand
doi: 10.1038/s41591-026-04440-4 It is important, as I was at pains to emphasise in relation to the existing evidence base for GLP-1s themselves, not to overstate what phase 2 data of this kind can tell us